Biotechnology company
Appears in 4 stories
Co-marketing Leqembi and IQLIK in the US
Since 2023 the Alzheimer's drug Leqembi came with a catch: patients needed intravenous infusions at a clinic every two weeks for 18 months. On August 24, Eisai and Biogen removed that hurdle, making a subcutaneous autoinjector version, LEQEMBI IQLIK, available from the very first dose.
Updated Aug 25
Developer of diranersen, advancing to registrational trials
For decades, nearly every Alzheimer's drug that reached patients aimed at one target: a sticky protein called amyloid. On July 14, 2026, Biogen showed the first clinical evidence that hitting a different protein, tau, can also slow the disease.
Updated Jul 14
Developer and commercial owner of salanersen
Some children with spinal muscular atrophy get a one-time gene therapy, then slowly weaken again. There has been no clear next step for them. On June 4, 2026, the FDA gave Biogen's salanersen a designation meant to speed up that next step.
Updated Jun 4
Co-developer with rights to zorevunersen outside North America
Dravet syndrome is a severe genetic epilepsy that causes hundreds of seizures per month, cognitive decline, and a 15–20 percent mortality rate. For nearly five decades, no treatment addressed the underlying cause — including two drugs approved in the past eight years, which could only partially suppress symptoms.
Updated May 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
